Targeted proteomics via NULISAseq identifies blood‐detectable markers of disease progression in familial frontotemporal lobar degeneration

Abstract

Background: Recent technological advances have enhanced the precision of blood‐based multiplex proteomics and their application in Alzheimer's disease. However, these approaches remain underutilized in frontotemporal lobar degeneration (FTLD).

The paper